everyone to get the fire service elevator >> unfortunately - >> i wouldn't say not willing to use for an onyx i have optioned so i'll bring my bottles first and if i have another choice i'll use the system. i'll go to option a and b before c >> just one question i know i know the question. what's the fundamental purchase to the air reaccomplishment >> so for the purpose of having the air available. >> to be able to fight the fire without going up. we have protocols set up the cash bottles so when we come down to fight the fires and sometimes, we don't use the systems to put the fire out but to come back and take a breather and have the next firefighters go up and change the bottles >> it's a safety issue. >> i want to take a break from my rehab those fires are contained fires and it takes a long time to fight and maybe the sprinkleers were out so we have the health and safety of the firefighters to take a breather and check their vial signs and go back to work. >> any other questions or comments. is the presentation complete? >> yes. >> thank you very much for all that information. >> preside

the onyx connection is that we had an opportunity to start a clinical trial with carfilzomib, the realriver for their valuation, that really drove the sale to amgen recently. we had an opportunity to pair our drug with their drug early before it was approved and we're one of the few compounds now that is actually in substantial clinical trials. we're going to give an update on that data at a.s.h., the big blood cancer conference, at the end of the year and around the end of the year be able to tell folks what our plans are for 520, the multiple myeloma drug for next year. and there is a lot of reason to believe that the data will really encourage us to go forward into pivotal trials. >> i know a lot of people close to home have asthma. and i know that this is a faraway drug, but is it already worth talking about because it's such a huge opportunity? >> you know, you can't avoid one really exciting thing about the drug. we call it 502. it's a stage 2 antagonist, a new mechanism in asthma. what's incredible, it's oral, and it showed a statistically significant efficacy in a robust trial.